Sana Biotechnology Posts UP421 One-Year Success, Raises $133.7M, Plans SC451 IND
UP421 trial shows one-year safety and function of hypoimmune-modified islet cell transplants without immunosuppression, with C-peptide production and PET-MRI confirming cell survival. The company raised $133.7 million in 2025, holds $138.4 million cash, and expects to file an IND for SC451 and report first-in-human SG293 data this year.
1. UP421 One-Year Clinical Results
UP421, a hypoimmune-modified allogeneic pancreatic islet cell therapy, demonstrated safety and sustained function one year post-transplant in a type 1 diabetes patient without immunosuppression. C-peptide levels rose on mixed meal tests and PET-MRI scans at weeks 12 and 52 confirmed cell engraftment without immune detection.
2. SC451 and SG293 Pipeline Advances
SC451, an iPSC-derived, hypoimmune-modified islet therapy, has completed manufacturing and regulatory interactions, with an IND filing and Phase 1 trial anticipated this year. SG293, a CD8-targeted fusosome delivering CD19 CAR, showed deep B-cell depletion and immune reset in non-human primates and is slated to generate first-in-human data in blood cancers later this year.
3. Financial Position and Runway
Sana secured $133.7 million in 2025 through ATM and equity financings, ending Q4 with $138.4 million in cash. This funding supports operations into late 2026 and underpins upcoming clinical milestones for both SC451 and SG293.